基于成分-单药-组方策略的中药抑制SARS-CoV-2主蛋白酶活性研究进展  

Research progress in the inhibition of main protease activity of SARS-CoV-2 with traditional Chinese medicine based on the strategy of ingredient-single drug-prescription

作　　者：任帅伟 董欢欢 朱才庆 朱卫丰[1] REN Shuaiwei;DONG Huanhuan;ZHU Caiqing;ZHU Weifeng(School of Pharmacy,Jiangxi University of Traditional Chinese Medicine,Jiangxi Nanchang 330004,China;Jiangxi Medical Device Testing Center,Jiangxi Nanchang 330029,China)

机构地区：[1]江西中医药大学药学院,江西南昌330004 [2]江西省医疗器械检测中心,江西南昌330029

出　　处：《中国医院药学杂志》2024年第3期349-355,共7页Chinese Journal of Hospital Pharmacy

基　　金：中国博士后科学基金(编号:2020T130050ZX)。

摘　　要：新型冠状病毒(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)自从暴发以来对人类身体健康产生了严重威胁,主蛋白酶(Mpro)作为病毒基因复制和转录的主要参与酶,是研究抗新冠病毒药物的重要靶点。对于新型冠状病毒肺炎,中药防治具有巨大潜力,以经典方剂为基础开发的一些中药复方被应用于临床,取得了良好的效果。该文以天然活性成分-单味药-组方3个层面为基础,对SARS-CoV-2 Mpro以及相关中药抑制剂的研究进展进行综述,以期为开发出抗SARSCoV-2的中药特效药及中药复方提供思路。Novel coronavirus(SARS-CoV-2)has posed a serious threat to human health since its outbreak.Main protease(Mpro),as the main enzyme involved in viral gene replication and transcription,is an important target for the study of anti-novel coronavirus drugs.For corona virus disease 2019,traditional Chinese medicine(TCM)has great potential for prevention and treatment,and some TCM compound developed on the basis of classical formulas have been applied in clinical practice with good results.This paper reviewed the research progress in SARS-CoV-2 Mpro and related Chinese medicine inhibitors on the basis of three levels,namely,natural active ingredient-single drug-prescription,with a view to providing ideas for the development of potent TCM and TCM compound against SARS-CoV-2.

关 键 词：SARS-CoV-2 主蛋白酶 天然活性成分 组方 研究进展 

分 类 号：R282[医药卫生—中药学]